Ironwood Pharmaceuticals 관리

관리 기준 확인 3/4

Ironwood Pharmaceuticals CEO는 Tom McCourt, Mar2021 에 임명되었습니다 의 임기는 3.67 년입니다. 총 연간 보상은 $ 7.58M, 11% 로 구성됩니다. 11% 급여 및 89% 보너스(회사 주식 및 옵션 포함). 는 € 1.64M 가치에 해당하는 회사 주식의 0.32% 직접 소유합니다. 1.64M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 5.6 년입니다.

주요 정보

Tom McCourt

최고 경영자

US$7.6m

총 보상

CEO 급여 비율	11.0%
CEO 임기	3.7yrs
CEO 소유권	0.3%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	5.6yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Tom McCourt 의 보수는 Ironwood Pharmaceuticals 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$2m
Jun 30 2024	n/a	n/a	US$9m
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	US$8m	US$834k	-US$1b
Sep 30 2023	n/a	n/a	-US$952m
Jun 30 2023	n/a	n/a	-US$917m
Mar 31 2023	n/a	n/a	US$182m
Dec 31 2022	US$8m	US$805k	US$175m
Sep 30 2022	n/a	n/a	US$168m
Jun 30 2022	n/a	n/a	US$173m
Mar 31 2022	n/a	n/a	US$527m
Dec 31 2021	US$9m	US$732k	US$528m
Sep 30 2021	n/a	n/a	US$530m
Jun 30 2021	n/a	n/a	US$509m
Mar 31 2021	n/a	n/a	US$143m
Dec 31 2020	US$3m	US$576k	US$106m
Sep 30 2020	n/a	n/a	US$111m
Jun 30 2020	n/a	n/a	US$97m
Mar 31 2020	n/a	n/a	US$84m
Dec 31 2019	US$5m	US$511k	US$59m
Sep 30 2019	n/a	n/a	US$19m
Jun 30 2019	n/a	n/a	-US$153m
Mar 31 2019	n/a	n/a	-US$173m
Dec 31 2018	US$2m	US$465k	-US$194m
Sep 30 2018	n/a	n/a	-US$190m
Jun 30 2018	n/a	n/a	-US$71m
Mar 31 2018	n/a	n/a	-US$108m
Dec 31 2017	US$2m	US$450k	-US$55m

보상 대 시장: Tom 의 총 보상 ($USD 7.58M )은 German 시장( $USD 995.28K ).

보상과 수익: Tom 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Tom McCourt (67 yo)

3.7yrs

테뉴어

US$7,583,270

보상

Mr. Thomas A. McCourt, also known as Tom, serves as Director at Pliant Therapeutics, Inc. since March 08, 2023. He serves as Chief Executive Officer and Director of Ironwood Pharmaceuticals, Inc. since Jun...

리더십 팀

이름	위치	테뉴어	보상	소유권
Thomas McCourt	CEO & Director	3.7yrs	US$7.58m	0.32% € 1.6m
Sravan Emany	Senior VP	2.9yrs	US$2.76m	0.091% € 467.1k
John Minardo	Senior VP	3.3yrs	US$2.44m	0.079% € 406.7k
Michael Shetzline	Chief Medical Officer	5.8yrs	US$2.60m	0.16% € 804.5k
Andrew Davis	Senior VP & Chief Business Officer	2.8yrs	US$2.67m	0.10% € 523.4k
Ronald Silver	Corporate Controller & Principal Accounting Officer	5.6yrs	데이터 없음	0.042% € 217.2k
Rosario Lobrutto	VP & Global Head of Technical Operations	less than a year	데이터 없음	데이터 없음
Greg Martini	Vice President of Strategic Finance & Investor Relations	no data	데이터 없음	데이터 없음
Beth Calitri	VP of Corporate Communications & Media Relations	2.8yrs	데이터 없음	데이터 없음
Mike Nanfito	Vice President of Sales & Sales Excellence	3.2yrs	데이터 없음	데이터 없음
Susanna Huh	VP & Head of Clinical Development	2.2yrs	데이터 없음	데이터 없음
Matt Roache	Director of Investor Relations	no data	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

47yo

평균 연령

경험이 풍부한 관리: I76 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Thomas McCourt	CEO & Director	3.4yrs	US$7.58m	0.32% € 1.6m
Jay Shepard	Independent Director	3.9yrs	US$300.71k	0.079% € 404.7k
Perry Halushka	Member of Pharmaceuticals Advisory Committee	no data	데이터 없음	데이터 없음
Alexander Denner	Independent Director	4yrs	US$300.69k	0.095% € 486.4k
Mark Currie	Independent Director	5.6yrs	US$300.71k	0.36% € 1.8m
Andrew Dreyfus	Independent Director	8.6yrs	US$310.71k	0.12% € 601.9k
Michael Mendelsohn	Member of Pharmaceutical Advisory Committee	7.8yrs	데이터 없음	데이터 없음
Catherine Moukheibir	Independent Director	5.6yrs	US$310.69k	0.046% € 233.2k
Julie McHugh	Independent Chairman of the Board	10.8yrs	US$335.71k	0.10% € 523.9k
Marla Kessler	Independent Director	5.6yrs	US$300.71k	0.076% € 386.5k
Jon Duane	Independent Director	5.6yrs	US$305.71k	0.091% € 464.7k

5.6yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: I76 의 이사회는 경험(평균 재직 기간 5.6 년)으로 간주됩니다.

Ironwood Pharmaceuticals 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Insufficient new directors

Independent Director recently sold €479k worth of stock

CEO & Director recently sold €402k worth of stock

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

Senior VP recently bought €281k worth of stock

CEO & Director recently sold €337k worth of stock

Recent updates

Third quarter 2024 earnings released: EPS: US$0.02 (vs US$0.098 in 3Q 2023)

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for Full Year 2024

Investor sentiment deteriorates as stock falls 15%

Investor sentiment deteriorates as stock falls 31%

New minor risk - Shareholder dilution

New minor risk - Financial position

Second quarter 2024 earnings released: US$0.005 loss per share (vs US$6.84 loss in 2Q 2023)

Ironwood Pharmaceuticals, Inc. Revises Earnings Guidance for Its Fiscal Year 2024

New major risk - Share price stability

Ironwood Pharmaceuticals, Inc.(NasdaqGS:IRWD) dropped from Russell 2000 Growth-Defensive Index

Insufficient new directors

Independent Director recently sold €479k worth of stock

CEO & Director recently sold €402k worth of stock

Ironwood Pharmaceuticals, Inc. Revised Earnings Guidance for Its Fiscal Year 2024

First quarter 2024 earnings released: US$0.03 loss per share (vs US$0.30 profit in 1Q 2023)

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 18, 2024

New minor risk - Shareholder dilution

Ironwood Pharmaceuticals, Inc. Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

New minor risk - Insider selling

Full year 2023 earnings released: US$6.45 loss per share (vs US$1.13 profit in FY 2022)

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Fiscal Year 2023 and Provides Earnings Guidance for the Fiscal Year 2024

Ironwood Pharmaceuticals, Inc. provides Earnings Guidance for the Year 2023

Ironwood Pharmaceuticals, Inc. Provids Earnings Guidance for the Year 2023

Third quarter 2023 earnings released: EPS: US$0.10 (vs US$0.33 in 3Q 2022)

Ironwood Pharmaceuticals, Inc. Releases New IBS-C and CIC Data at the American College of Gastroenterology 2023 Annual Scientific Meeting

Ironwood Pharmaceuticals, Inc. Presents Positive Final Data from Stars Nutrition, A Phase II Study of Apraglutide in Short Bowel Syndrome with Intestinal Failure (SBS-IF) and Colon in Continuity

Ironwood to Present New Data at NASPGHAN Annual Meeting Reinforcing Impact of Linaclotide on Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Senior VP recently bought €281k worth of stock

New major risk - Negative shareholders equity

Second quarter 2023 earnings released: US$6.84 loss per share (vs US$0.24 profit in 2Q 2022)

Ironwood Pharmaceuticals, Inc. Revises Financial Guidance for the Year 2023

Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients Ages 6-17 Years-Old

CEO & Director recently sold €337k worth of stock

Ironwood Pharmaceuticals, Inc. Presents Results from Phase III Clinical Trial in Pediatric Patients

First quarter 2023 earnings released: EPS: US$0.30 (vs US$0.25 in 1Q 2022)

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

Senior VP & COO recently sold €366k worth of stock

Full year 2022 earnings released: EPS: US$1.13 (vs US$3.26 in FY 2021)

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for 2023

Ironwood Pharmaceuticals Announces FDA Filing Acceptance and Priority Review of Supplemental New Drug Application for LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Full Year 2023

Senior VP & COO recently sold €314k worth of stock

Senior VP recently sold €74k worth of stock

Third quarter 2022 earnings released: EPS: US$0.33 (vs US$0.34 in 3Q 2021)

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of Linzess® (Linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation

Senior VP & COO recently sold €335k worth of stock

Second quarter 2022 earnings released: EPS: US$0.24 (vs US$2.42 in 2Q 2021)

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Year 2022

High number of new directors

Ironwood Pharmaceuticals, Inc. to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022

First quarter 2022 earnings released: EPS: US$0.25 (vs US$0.25 in 1Q 2021)

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022

High number of new directors

Ironwood Pharmaceuticals, Inc., Annual General Meeting, Jun 01, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Ironwood Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2022

Ironwood Pharmaceuticals, Inc. Provides Financial Guidance for the Full Year 2022

Executive Chairman of the Board recently sold €98k worth of stock

Third quarter 2021 earnings released: EPS US$0.34 (vs US$0.21 in 3Q 2020)

Ironwood Pharmaceuticals Announces FDA Approval of Revised Linzess® (Linaclotide) Label

Second quarter 2021 earnings released: EPS US$2.42 (vs US$0.16 in 2Q 2020)

Principal Accounting Officer, CFO, Senior VP & Treasurer Gina Consylman has left the company

Ironwood Pharmaceuticals Announces The American Journal of Gastroenterology Publishes Full Results from Positive LINZESS® (linaclotide) Phase IIIb Trial in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Ironwood Pharmaceuticals, Inc. Maintains Earnings Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$0.25 (vs US$0.021 in 1Q 2020)

CEO & Director Mark Mallon has left the company